Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027

Voyager Therapeutics, Inc.

2025-Q1 EPS reported -$0.53 revenue$6,473,000

Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).
Cash, cash equivalents & marketable securities $295M; expects runway into mid-2027.
R&D expenses $31.5M (+16% YoY); G&A $9.6M (+12% YoY).
VY1706 tau silencing gene therapy achieved up to 73% tau mRNA knockdown in NHPs; IND/CTA filings expected 2026.
Neurocrine-partnered FA and GBA1 IND submissions on track for 2025; up to $35M milestone potential 2025-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.